On Jul. 29, 2026, Octapharma, the largest privately owned and independent plasma fractionator in the world, has formally announced plans to establish its first-ever United States-based manufacturing and production site at the Palmetto Research Park in Rock Hill, South Carolina. The $1.5 billion project is expected to bring 1,500 full-time jobs to South Carolina, making this one of the largest private biomedical investments in the state’s history.  

Once operations commence, this facility will produce critical, life-saving medicines from Octapharma’s portfolio of plasma-derived therapies, strengthening the domestic biomedical supply chain while also complementing the company’s global manufacturing capabilities. Octapharma’s Rock Hill site will also produce bleeding management and trauma care products for national security and emergency preparedness needs.

This announcement follows a thorough planning and zoning process coordinated with officials from Rock Hill and York County, and close partnership with local, state and federal leaders.